Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

106.25 -1.83 (-1.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
21 22 Next >
3 Surefire Growth Stocks You Can Buy Right Now
Maybe there's no such thing as a sure thing. But these stocks could come close. 
Via The Motley Fool
3 Stocks That Could Soar Whether There's a New Bull Market or Not
These stocks could enjoy their own bull markets regardless of what the overall market does. 
Via The Motley Fool
Axsome Therapeutics to Present at the SVB Securities Global Biopharma Conference
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27
Axsome to host conference call and webcast on Monday, Feb. 27, 2023, at 8:00 a.m. ET 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
The Latest Analyst Ratings for Axsome Therapeutics
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $1,900 Today
Via Benzinga
Here's How Much $100 Invested In Axsome Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
The Ultimate Growth Stocks to Buy With $300 Right Now
These three companies should deliver inflation-busting long-term growth. 
Via The Motley Fool
2 Promising New Growth Stocks to Watch in 2023
These stocks have plenty of room to run. 
Via The Motley Fool
3 Unstoppable Stocks to Keep Buying in 2023
These companies have what it takes to drive long-term share performance. 
Via The Motley Fool
2 Stocks That Could Double Your Money in 2023
These biotechs could crush the market, but there is more to the story. 
Via The Motley Fool
These Stocks Jumped 100% and 30% Last Year. Here's Why They're Still a Buy.
These stocks look cheap if you take a long-term view. 
Via The Motley Fool
5 Top Stocks to Buy to Start the New Year Right
This may be the easiest of your New Year's resolutions. And it could pay off big. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
How Is The Market Feeling About Axsome Therapeutics?
Axsome Therapeutics's (NASDAQ:AXSM) short percent of float has fallen 7.06% since its last report. The company recently reported that it has 7.37 million shares sold short, which is 20.81% of all... 
Via Benzinga
100 Best Stocks Of 2022: Fossil Fuel Ignites, Solar Shines, Meds Make Miracles
Energy and medical plays top the 100 Best Stocks of 2022. It makes sense, given world events that shifted the first-quarter playing field. 
Via Investor's Business Daily
2 Growth Stocks to Buy Heading Into 2023
These biotechs are far from having achieved their full potential. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
2 Top Biotech Stocks to Buy for the Long Haul
These mid-cap biotechs are solid long-term choices. 
Via The Motley Fool
Got $5,000? 2 Unstoppable Stocks to Buy and Hold
These businesses are growing and can be excellent places to make a sizable investment right now. 
Via The Motley Fool
Better Buy: Moderna vs Axsome
Revenue prospects look promising for both of these biotech companies. 
Via The Motley Fool
The 7 Hottest Biotech Stocks to Own in 2023 and Beyond
Biotech is one of the safest, recession-proof sectors on the market. It's why we're going after the hottest biotech stocks in the New Year. 
Via InvestorPlace
Should You Buy Stocks If a Recession Is Coming in 2023? Here's What History Shows.
Stocks usually go down during recessions, but long-term investors can still come out on top. 
Via The Motley Fool
After Jumping 100%, Is Axsome a Buy Before 2023?
Axsome's revenue story is just getting started. 
Via The Motley Fool
Is Anavex Life Sciences a Buy?
It still needs to prove that its lead program is as effective as it claims for treating Alzheimer's. 
Via The Motley Fool
Where to Invest $1,000 Before the End of 2022
Right now is the perfect time to put your money to work. 
Via The Motley Fool
3 High-Flying Stocks to Buy and Hold If a Recession Is on the Way
An economic downturn shouldn't hurt these stocks. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
These Were The Five Best And Worst Performing Mid-Cap Stocks In November 2022
In November, the Dow Jones gained around 7%, the S&P 500 gained 8.4%, and the Nasdaq gained 9.1%. The S&P Mid-Cap 400 performance was in line with major indices. Let’s take a look at the five best and... 
Via Talk Markets
3 Red-Hot Stocks That Could Continue to Beat the Market
The success these stocks achieved in 2022 could be just the beginning. 
Via The Motley Fool
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.